Jun Kyu Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun Kyu Lee has a total of 369 co-authors. Here are the top co-authors by number of shared publications:
- Sang Hyub Lee
Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
21 shared publications Won Jae Yoon
20 shared publicationsYong Bum Yoon
From the *Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea; †Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea; ‡Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea; and §Department of Internal Medicine, Dongguk University Ilsan Hospital, Graduate School of Medicine, Dongguk University-Seoul, Seoul, Korea
19 shared publicationsYong-Tae Kim
From the *Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea; †Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea; ‡Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea; and §Department of Internal Medicine, Dongguk University Ilsan Hospital, Graduate School of Medicine, Dongguk University-Seoul, Seoul, Korea
16 shared publications- Dong Kee Jang
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
14 shared publications - Hyoun Woo Kang
Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
14 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (1)
Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial
Background and Aims: Remimazolam, a new ultra‐short‐acting benzodiazepine, is a safe and effective option for procedural sedation. Nevertheless, to date, no study has directly compared remimazolam and midazolam in diagnostic upper gastrointestinal endoscopy. This study aimed to evaluate the efficacy and safety of remimazolam compared with those of midazolam in this setting. Methods: This multicenter, single‐blind, randomized, positive‐control, superiority, investigator‐initiated phase III trial enrolled patients who were scheduled to undergo diagnostic upper gastrointestinal endoscopy at seven academic teaching hospitals from April 2023 to January 2024. Participants were randomly assigned to receive remimazolam or midazolam (1:1 ratio). The primary endpoint was total procedure time, defined as the duration from the first sedative administration to discharge. Results: Of 133 randomized patients, 132 (remimazolam group, n = 66; midazolam group, n = 66) underwent upper endoscopy with sedation. The total procedure time was significantly shorter in the remimazolam group (30.3 vs. 48.5 min, p < 0.001). Sedation‐related times (i.e., induction, sedation, recovery, and discharge times) were also significantly shorter in the remimazolam group (all p < 0.001). The incidence of adverse events did not significantly differ between the groups; however, the incidence rates of hypotension, bradycardia, and paradoxical reactions were lower in the remimazolam group. When compared to previous sedation experiences, patient satisfaction was higher in the remimazolam group ( p < 0.001). Conclusions: Compared with midazolam, the use of remimazolam in diagnostic upper gastrointestinal endoscopy allows for faster sedation induction and recovery, more rapid discharge, and higher patient satisfaction compared with previous sedation experiences, while maintaining a safety profile similar to that of midazolam. Trial registration: ClinicalTrials.gov (NCT05836545)
- 24 November 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (1)
Open AccessRemimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial
Background and Aims: Remimazolam, a new ultra‐short‐acting benzodiazepine, is a safe and effective option for procedural sedation. Nevertheless, to date, no study has directly compared remimazolam and midazolam in diagnostic upper gastrointestinal endoscopy. This study aimed to evaluate the efficacy and safety of remimazolam compared with those of midazolam in this setting. Methods: This multicenter, single‐blind, randomized, positive‐control, superiority, investigator‐initiated phase III trial enrolled patients who were scheduled to undergo diagnostic upper gastrointestinal endoscopy at seven academic teaching hospitals from April 2023 to January 2024. Participants were randomly assigned to receive remimazolam or midazolam (1:1 ratio). The primary endpoint was total procedure time, defined as the duration from the first sedative administration to discharge. Results: Of 133 randomized patients, 132 (remimazolam group, n = 66; midazolam group, n = 66) underwent upper endoscopy with sedation. The total procedure time was significantly shorter in the remimazolam group (30.3 vs. 48.5 min, p < 0.001). Sedation‐related times (i.e., induction, sedation, recovery, and discharge times) were also significantly shorter in the remimazolam group (all p < 0.001). The incidence of adverse events did not significantly differ between the groups; however, the incidence rates of hypotension, bradycardia, and paradoxical reactions were lower in the remimazolam group. When compared to previous sedation experiences, patient satisfaction was higher in the remimazolam group ( p < 0.001). Conclusions: Compared with midazolam, the use of remimazolam in diagnostic upper gastrointestinal endoscopy allows for faster sedation induction and recovery, more rapid discharge, and higher patient satisfaction compared with previous sedation experiences, while maintaining a safety profile similar to that of midazolam. Trial registration: ClinicalTrials.gov (NCT05836545)
- Open Access
- 30 May 2025
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 58 (3) , 370-376
Remimazolam, a novel drug, for safe and effective endoscopic sedation
Remimazolam is a novel benzodiazepine with unique pharmacokinetic and pharmacodynamic properties, making it an ideal candidate for sedation during endoscopic procedures. Distinguished by its rapid onset and short duration of action, remimazolam offers a safer and more efficient alternative to traditional sedatives, such as midazolam and propofol, with fewer side effects, such as hypotension, bradycardia, and respiratory depression. This article reviews the characteristics of remimazolam and its practical advantages, including ease of use, quick recovery time, and minimal residual sedation, emphasizing its potential to improve patient safety and procedural efficiency in clinical endoscopy settings.
- 30 May 2025
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 58 (3) , 370-376
Open AccessRemimazolam, a novel drug, for safe and effective endoscopic sedation
Remimazolam is a novel benzodiazepine with unique pharmacokinetic and pharmacodynamic properties, making it an ideal candidate for sedation during endoscopic procedures. Distinguished by its rapid onset and short duration of action, remimazolam offers a safer and more efficient alternative to traditional sedatives, such as midazolam and propofol, with fewer side effects, such as hypotension, bradycardia, and respiratory depression. This article reviews the characteristics of remimazolam and its practical advantages, including ease of use, quick recovery time, and minimal residual sedation, emphasizing its potential to improve patient safety and procedural efficiency in clinical endoscopy settings.
- 21 May 2025
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (12) , 4894-4903
Temple stay diet and its impact on gut microbiome and irritable bowel syndrome: a prospective cohort study
Background/Aims: Irritable Bowel Syndrome (IBS) significantly impacts quality of life, with effective treatment challenged by its multifactorial pathogenesis. A temple stay program incorporating a vegetarian diet may benefit IBS by modulating the gut microbiota. Methods: In this prospective cohort study, 61 patients with diarrhea-predominant IBS (IBS-D) or mixed bowel habit IBS (IBS-M) participated in a 4 day temple stay program following a 1 week washout period. IBS symptom severity, psychological stress, and fecal microbiota composition were assessed before, immediately after, and two weeks post-intervention using the IBS Severity Scoring System (IBS-SSS) and 16S rRNA gene sequencing. Results: A subset of participants demonstrated improvements in IBS symptom severity, particularly those who exhibited marked compositional shifts in their gut microbiota, as defined by beta-diversity (weighted UniFrac distance). These microbiome responders tended to show increased levels of beneficial bacteria such as Faecalibacterium and reduced levels of opportunistic taxa including Klebsiella and Enterococcus. A significant correlation was observed between the degree of microbiota change and improvement in IBS-SSS scores. Responders also differed from non-responders in baseline gut microbiota features, including lower alpha diversity and reduced abundance of commensal genera. Conclusions: The temple stay program may provide clinical and microbial benefits in a subset of individuals with IBS, particularly those with baseline gut dysbiosis. These findings support the potential role of personalized, microbiome-informed dietary interventions in managing IBS.
- 21 May 2025
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (12) , 4894-4903
Temple stay diet and its impact on gut microbiome and irritable bowel syndrome: a prospective cohort study
Background/Aims: Irritable Bowel Syndrome (IBS) significantly impacts quality of life, with effective treatment challenged by its multifactorial pathogenesis. A temple stay program incorporating a vegetarian diet may benefit IBS by modulating the gut microbiota. Methods: In this prospective cohort study, 61 patients with diarrhea-predominant IBS (IBS-D) or mixed bowel habit IBS (IBS-M) participated in a 4 day temple stay program following a 1 week washout period. IBS symptom severity, psychological stress, and fecal microbiota composition were assessed before, immediately after, and two weeks post-intervention using the IBS Severity Scoring System (IBS-SSS) and 16S rRNA gene sequencing. Results: A subset of participants demonstrated improvements in IBS symptom severity, particularly those who exhibited marked compositional shifts in their gut microbiota, as defined by beta-diversity (weighted UniFrac distance). These microbiome responders tended to show increased levels of beneficial bacteria such as Faecalibacterium and reduced levels of opportunistic taxa including Klebsiella and Enterococcus. A significant correlation was observed between the degree of microbiota change and improvement in IBS-SSS scores. Responders also differed from non-responders in baseline gut microbiota features, including lower alpha diversity and reduced abundance of commensal genera. Conclusions: The temple stay program may provide clinical and microbial benefits in a subset of individuals with IBS, particularly those with baseline gut dysbiosis. These findings support the potential role of personalized, microbiome-informed dietary interventions in managing IBS.
- Open Access
- 24 August 2024
- Published by Springer Nature in npj Digital Medicine
- Vol. 7 (1) , 1-10
Deep learning-based prediction of Clostridioides difficile infection caused by antibiotics using longitudinal electronic health records
Clostridioides difficile infection (CDI) is a major cause of antibiotic-associated diarrhea and colitis. It is recognized as one of the most significant hospital-acquired infections. Although CDI can develop severe complications and spores of Clostridioides difficile can be transmitted by the fecal-oral route, CDI is occasionally overlooked in clinical settings. Thus, it is necessary to monitor high CDI risk groups, particularly those undergoing antibiotic treatment, to prevent complications and spread. We developed and validated a deep learning-based model to predict the occurrence of CDI within 28 days after starting antibiotic treatment using longitudinal electronic health records. For each patient, timelines of vital signs and laboratory tests with a 35-day monitoring period and a patient information vector consisting of age, sex, comorbidities, and medications were constructed. Our model achieved the prediction performance with an area under the receiver operating characteristic curve of 0.952 (95% CI: 0.932–0.973) in internal validation and 0.972 (95% CI: 0.968–0.975) in external validation. Platelet count and body temperature emerged as the most important features. The risk score, the output value of the model, exhibited a consistent increase in the CDI group, while the risk score in the non-CDI group either maintained its initial value or decreased. Using our CDI prediction model, high-risk patients requiring symptom monitoring can be identified. This could help reduce the underdiagnosis of CDI, thereby decreasing transmission and preventing complications.
- 24 August 2024
- Published by Springer Nature in npj Digital Medicine
- Vol. 7 (1) , 1-10
Open AccessDeep learning-based prediction of Clostridioides difficile infection caused by antibiotics using longitudinal electronic health records
Clostridioides difficile infection (CDI) is a major cause of antibiotic-associated diarrhea and colitis. It is recognized as one of the most significant hospital-acquired infections. Although CDI can develop severe complications and spores of Clostridioides difficile can be transmitted by the fecal-oral route, CDI is occasionally overlooked in clinical settings. Thus, it is necessary to monitor high CDI risk groups, particularly those undergoing antibiotic treatment, to prevent complications and spread. We developed and validated a deep learning-based model to predict the occurrence of CDI within 28 days after starting antibiotic treatment using longitudinal electronic health records. For each patient, timelines of vital signs and laboratory tests with a 35-day monitoring period and a patient information vector consisting of age, sex, comorbidities, and medications were constructed. Our model achieved the prediction performance with an area under the receiver operating characteristic curve of 0.952 (95% CI: 0.932–0.973) in internal validation and 0.972 (95% CI: 0.968–0.975) in external validation. Platelet count and body temperature emerged as the most important features. The risk score, the output value of the model, exhibited a consistent increase in the CDI group, while the risk score in the non-CDI group either maintained its initial value or decreased. Using our CDI prediction model, high-risk patients requiring symptom monitoring can be identified. This could help reduce the underdiagnosis of CDI, thereby decreasing transmission and preventing complications.
- Open Access
- 31 July 2024
- Published by Korean Pancreatobiliary Association in The Korean Journal of Pancreas and Biliary Tract
- Vol. 29 (3) , 69-84
Guideline for Minimizing Radiation Exposure of Interventionalists during Fluoroscopy-Guided Interventional Procedures
As fluoroscopy-guided interventional procedures gain popularity, the associated health threats from radiation exposure to interventionalists during these procedures are increasing. Therefore, an understanding of the potential risks of radiation and careful consideration on minimizing exposure to radiation during the procedures are of paramount importance. The Korean Pancreatobiliary Association has developed a clinical practice guideline to minimize radiation exposure during fluoroscopy-guided interventional procedures. This guideline provides recommendations to deal with the risk of radiation exposure to interventionalists who perform fluoroscopy-guided procedures, and emphasizes the importance of proper and practical approaches to avoid unnecessary radiation exposure.
- 31 July 2024
- Published by Korean Pancreatobiliary Association in The Korean Journal of Pancreas and Biliary Tract
- Vol. 29 (3) , 69-84
Open AccessGuideline for Minimizing Radiation Exposure of Interventionalists during Fluoroscopy-Guided Interventional Procedures
As fluoroscopy-guided interventional procedures gain popularity, the associated health threats from radiation exposure to interventionalists during these procedures are increasing. Therefore, an understanding of the potential risks of radiation and careful consideration on minimizing exposure to radiation during the procedures are of paramount importance. The Korean Pancreatobiliary Association has developed a clinical practice guideline to minimize radiation exposure during fluoroscopy-guided interventional procedures. This guideline provides recommendations to deal with the risk of radiation exposure to interventionalists who perform fluoroscopy-guided procedures, and emphasizes the importance of proper and practical approaches to avoid unnecessary radiation exposure.
- 1 November 2023
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 21 (6) , 537-542
Electroacupuncture for abdominal pain relief in patients with acute pancreatitis: A three-arm randomized controlled trial
- 1 November 2023
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 21 (6) , 537-542
Electroacupuncture for abdominal pain relief in patients with acute pancreatitis: A three-arm randomized controlled trial
- Open Access
- 15 September 2023
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 34 (9) , 932-942
The Awareness and Experience About Endoscopic Adverse Events Among South Korean Endoscopists
Background/Aims: The number of endoscopic procedures and related adverse events is increasing. We investigated South Korean endoscopists’ awareness and experience of endoscopic adverse events. Materials and Methods: We used Google Forms to conduct an online questionnaire survey among South Korean endoscopists from December 11 to 29, 2020. The survey comprised 30 questions developed by members of the Quality Management Committee of the Korean Society of Gastrointestinal Endoscopy. Results: In total, 475 endoscopists participated in the survey. Of these, 454 (95.6%) were board-certified gastroenterologists and 255 (53.7%) had >10 years of endoscopy experience. Most participants had experienced serious adverse events requiring hospitalization (80.4%, 382/475); however, only 100 (21.1%) were aware of programs for the prevention and management of adverse endoscopic events in their affiliated endoscopy centers. Most participants (98.5%, 468/475) agreed with the need for education on medical accidents for healthcare workers. Responses were inconsistent regarding the definition of adverse events formulated by the 2010 American Society for Gastrointestinal Endoscopy Workshop. Most participants were not aware of the minimal standard terminology (76.6%, 364/475) and had not used it when writing endoscopy reports (88.8%, 422/475). Responses were inconsistent regarding which events to record in endoscopy records. Conclusion: Further discussion on the nationwide adverse-event reporting system and education program for adverse events related to endoscopy is needed to ensure the safety of patients and endoscopists.
- 15 September 2023
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 34 (9) , 932-942
Open AccessThe Awareness and Experience About Endoscopic Adverse Events Among South Korean Endoscopists
Background/Aims: The number of endoscopic procedures and related adverse events is increasing. We investigated South Korean endoscopists’ awareness and experience of endoscopic adverse events. Materials and Methods: We used Google Forms to conduct an online questionnaire survey among South Korean endoscopists from December 11 to 29, 2020. The survey comprised 30 questions developed by members of the Quality Management Committee of the Korean Society of Gastrointestinal Endoscopy. Results: In total, 475 endoscopists participated in the survey. Of these, 454 (95.6%) were board-certified gastroenterologists and 255 (53.7%) had >10 years of endoscopy experience. Most participants had experienced serious adverse events requiring hospitalization (80.4%, 382/475); however, only 100 (21.1%) were aware of programs for the prevention and management of adverse endoscopic events in their affiliated endoscopy centers. Most participants (98.5%, 468/475) agreed with the need for education on medical accidents for healthcare workers. Responses were inconsistent regarding the definition of adverse events formulated by the 2010 American Society for Gastrointestinal Endoscopy Workshop. Most participants were not aware of the minimal standard terminology (76.6%, 364/475) and had not used it when writing endoscopy reports (88.8%, 422/475). Responses were inconsistent regarding which events to record in endoscopy records. Conclusion: Further discussion on the nationwide adverse-event reporting system and education program for adverse events related to endoscopy is needed to ensure the safety of patients and endoscopists.
- Open Access
- 30 July 2023
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 56 (4) , 499-509
Medical disputes related to advanced endoscopic procedures with endoscopic retrograde cholangiopancreatography or endoscopic ultrasonography for the management of pancreas and biliary tract diseases
Background/Aims: This study aimed to evaluate the characteristics of endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasonography (EUS)-related adverse events (AEs) that eventually lead to medical disputes or claims on medical professional liability.Methods: Medical disputes for ERCP/EUS-related AEs filed in the Korea Medical Dispute Mediation and Arbitration Agency between April 2012 and August 2020 were evaluated using corresponding medical records. AEs were categorized into three sections: procedure-related, sedation-related, and safety-related AEs.Results: Among a total of 34 cases, procedure-related AEs were 26 (76.5%; 12 duodenal perforations, 7 post-ERCP pancreatitis, 5 bleedings, 2 perforations combined with post-ERCP pancreatitis); sedation-related AEs were 5 (14.7%; 4 cardiac arrests, 1 desaturation), and safety-related AEs were 5 (8.8%; 1 follow-up loss for stent removal, 1 asphyxia, 1 fall). Regarding clinical outcomes, 20 (58.8%) were fatal and eventually succumbed to AEs. For the types of medical institutions, 21 cases (61.8%) occurred at tertiary or academic hospitals, and 13 (38.2%) occurred at community hospitals.Conclusions: The ERCP/EUS-related AEs filed in Korea Medical Dispute Mediation and Arbitration Agency showed distinct features: duodenal perforation was the most frequent AE, and clinical outcomes were fatal, resulting in at least more than permanent physical impairment.
- 30 July 2023
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 56 (4) , 499-509
Open AccessMedical disputes related to advanced endoscopic procedures with endoscopic retrograde cholangiopancreatography or endoscopic ultrasonography for the management of pancreas and biliary tract diseases
Background/Aims: This study aimed to evaluate the characteristics of endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasonography (EUS)-related adverse events (AEs) that eventually lead to medical disputes or claims on medical professional liability.Methods: Medical disputes for ERCP/EUS-related AEs filed in the Korea Medical Dispute Mediation and Arbitration Agency between April 2012 and August 2020 were evaluated using corresponding medical records. AEs were categorized into three sections: procedure-related, sedation-related, and safety-related AEs.Results: Among a total of 34 cases, procedure-related AEs were 26 (76.5%; 12 duodenal perforations, 7 post-ERCP pancreatitis, 5 bleedings, 2 perforations combined with post-ERCP pancreatitis); sedation-related AEs were 5 (14.7%; 4 cardiac arrests, 1 desaturation), and safety-related AEs were 5 (8.8%; 1 follow-up loss for stent removal, 1 asphyxia, 1 fall). Regarding clinical outcomes, 20 (58.8%) were fatal and eventually succumbed to AEs. For the types of medical institutions, 21 cases (61.8%) occurred at tertiary or academic hospitals, and 13 (38.2%) occurred at community hospitals.Conclusions: The ERCP/EUS-related AEs filed in Korea Medical Dispute Mediation and Arbitration Agency showed distinct features: duodenal perforation was the most frequent AE, and clinical outcomes were fatal, resulting in at least more than permanent physical impairment.
- Open Access
- 15 June 2023
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 18 (2) , 245-256
The Impact of Sedation on Cardio-Cerebrovascular Adverse Events after Surveillance Esophagogastroduodenoscopy in Patients with Gastric Cancer: A Nationwide Population-Based Cohort Study
Sang Yoon Kim, Jun Kyu Lee, Kwang Hyuck Lee, Jae-Young Jang, Byung-Wook Kim, Endoscopic Sedation Committee of Korean Society of Gastrointestinal Endoscopy (KSGE). Gut and Liver 2024;18:245-56. https://doi.org/10.5009/gnl230043
- 15 June 2023
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 18 (2) , 245-256
Open AccessThe Impact of Sedation on Cardio-Cerebrovascular Adverse Events after Surveillance Esophagogastroduodenoscopy in Patients with Gastric Cancer: A Nationwide Population-Based Cohort Study
Sang Yoon Kim, Jun Kyu Lee, Kwang Hyuck Lee, Jae-Young Jang, Byung-Wook Kim, Endoscopic Sedation Committee of Korean Society of Gastrointestinal Endoscopy (KSGE). Gut and Liver 2024;18:245-56. https://doi.org/10.5009/gnl230043
- Open Access
- 30 April 2023
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 12 (2) , 64-68
Endoscopic duodenal mucosal resurfacing for treating obesity and metabolic diseases: State-of-the-art review
Sang Hoon Kim and Jun Kyu Lee. Int J Gastrointest Interv 2023;12:64-8. https://doi.org/10.18528/ijgii220018
- 30 April 2023
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 12 (2) , 64-68
Open AccessEndoscopic duodenal mucosal resurfacing for treating obesity and metabolic diseases: State-of-the-art review
Sang Hoon Kim and Jun Kyu Lee. Int J Gastrointest Interv 2023;12:64-8. https://doi.org/10.18528/ijgii220018